Colchicine use might be associated with lower mortality in COVID-19 patients: A meta-analysis.
Eur J Clin Invest
; 51(9): e13645, 2021 Sep.
Article
in English
| MEDLINE | ID: covidwho-1286673
ABSTRACT
BACKGROUND:
Colchicine was recently repurposed for the management of coronavirus disease 2019 (COVID-19). This rapid review and meta-analysis aimed to assess colchicine's impact on mortality outcomes in COVID-19 patients. MATERIALS ANDMETHODS:
We systematically searched PubMed, EMBASE, Google Scholar since their inception till 25/03/2021 for observational or controlled studies that reported mortality as an outcome. The mortality odd ratios were generated with their corresponding 95% confidence intervals utilizing the random-effects model.RESULTS:
Nine studies comprising 5522 patients met our inclusion criteria. Our meta-analysis revealed significantly lower mortality in the colchicine group (OR 0.35, 95% CI 0.25-0.48, I2 0%) compared with controls. A subgroup analysis limited to hospitalized patients (OR 0.35, 95% CI 0.25-0.50, I2 0%) revealed similarly lower mortality in the colchicine group.CONCLUSIONS:
This meta-analysis suggests a mortality benefit with colchicine when used in the treatment of COVID-19 patients. The majority of included studies were observational; thus, the findings of this review need to be further supported by the results of ongoing trials.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Colchicine
/
Tubulin Modulators
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Language:
English
Journal:
Eur J Clin Invest
Year:
2021
Document Type:
Article
Affiliation country:
Eci.13645
Similar
MEDLINE
...
LILACS
LIS